Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.12 is considered Undervalued compared with the five-year average of 12.48. The fair price of Pacira Biosciences Inc (PCRX) is between 22.22 to 47.67 according to relative valuation method. Compared to the current price of 21.28 USD , Pacira Biosciences Inc By Undervalued By 4.23%.

Relative Value

Fair Zone

22.22-47.67

Current Price：21.28

4.23%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Pacira Biosciences Inc (PCRX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Pacira Biosciences Inc (PCRX) has a current Price-to-Book (P/B) ratio of 1.45. Compared to its 3-year average P/B ratio of 1.57, the current P/B ratio is approximately -7.79% higher. Relative to its 5-year average P/B ratio of 2.43, the current P/B ratio is about -40.58% higher. Pacira Biosciences Inc (PCRX) has a Forward Free Cash Flow (FCF) yield of approximately 11.80%. Compared to its 3-year average FCF yield of 13.27%, the current FCF yield is approximately -11.07% lower. Relative to its 5-year average FCF yield of 9.19%, the current FCF yield is about 28.48% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PCRX competitors is 128.17, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX.O) exhibits a P/S ratio of 1.34, which is -98.96% above the industry average. Given its robust revenue growth of 5.14%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PCRX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PCRX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PCRX currently overvalued or undervalued?

What is Pacira Biosciences Inc (PCRX) fair value?

PCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Pacira Biosciences Inc (PCRX) is between 22.22 to 47.67 according to relative valuation method.

How does PCRX's valuation metrics compare to the industry average?

The average P/S ratio for PCRX's competitors is 128.17, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX) exhibits a P/S ratio of 1.34, which is -98.96% above the industry average. Given its robust revenue growth of 5.14%, this premium appears unsustainable.

What is the current P/B ratio for Pacira Biosciences Inc (PCRX) as of Mar 03 2026?

As of Mar 03 2026, Pacira Biosciences Inc (PCRX) has a P/B ratio of 1.45. This indicates that the market values PCRX at 1.45 times its book value.

What is the current FCF Yield for Pacira Biosciences Inc (PCRX) as of Mar 03 2026?

As of Mar 03 2026, Pacira Biosciences Inc (PCRX) has a FCF Yield of 11.80%. This means that for every dollar of Pacira Biosciences Inc's market capitalization, the company generates 11.80 cents in free cash flow.

What is the current Forward P/E ratio for Pacira Biosciences Inc (PCRX) as of Mar 03 2026?

As of Mar 03 2026, Pacira Biosciences Inc (PCRX) has a Forward P/E ratio of 7.12. This means the market is willing to pay $7.12 for every dollar of Pacira Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Pacira Biosciences Inc (PCRX) as of Mar 03 2026?

As of Mar 03 2026, Pacira Biosciences Inc (PCRX) has a Forward P/S ratio of 1.34. This means the market is valuing PCRX at $1.34 for every dollar of expected revenue over the next 12 months.

PCRX Valuation